Adoptive immunotherapy for EBV-associated malignancies

Leukemia and Lymphoma

Volumn 46, Issue 1, 2005, Pages 1-10

  Gottschalk, Stephen ^a   Heslop, Helen E ^a   Rooney, Cliona M ^a  

^a CENTER FOR CELL AND GENE THERAPY   (United States)

Author keywords

Adoptive immunotherapy; EBV associated malignancies

Indexed keywords

ANTINEOPLASTIC AGENT; B LYMPHOCYTE ANTIBODY; CANCER VACCINE; CISPLATIN; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYTOKINE; DENDRITIC CELL VACCINE; EPSTEIN BARR VIRUS ANTIGEN; EPSTEIN BARR VIRUS PROTEIN; EPSTEIN BARR VIRUS VACCINE; FLUDARABINE; FLUOROURACIL; GANCICLOVIR; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RITUXIMAB; TACROLIMUS; THYMIDINE KINASE; UNCLASSIFIED DRUG; VIRUS PROTEIN;

ADOPTIVE IMMUNOTHERAPY; ANTINEOPLASTIC ACTIVITY; BURKITT LYMPHOMA; CANCER ADJUVANT THERAPY; CANCER IMMUNOTHERAPY; CANCER PREVENTION; CANCER RESISTANCE; CELL BASED GENE THERAPY; CLINICAL TRIAL; CYTOKINE RELEASE; CYTOTOXIC T LYMPHOCYTE; DOWN REGULATION; DRUG RESPONSE; EPSTEIN BARR VIRUS; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HODGKIN DISEASE; HUMAN; LATENT VIRUS INFECTION; LYMPHOPROLIFERATIVE DISEASE; MALIGNANT NEOPLASTIC DISEASE; NASOPHARYNX CARCINOMA; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; VIRUS CARCINOGENESIS;

EPSTEIN-BARR VIRUS INFECTIONS; HUMANS; IMMUNOTHERAPY, ADOPTIVE; LYMPHOMA; NEOPLASMS;

EID: 12744274892     PISSN: 10428194     EISSN: None     Source Type: Journal    
DOI: 10.1080/10428190400002202     Document Type: Review

References (84)

1. Rickinson, A.B. and Kieff, E. (2001) Epstein-Barr Virus. In Fields Virolgy, edited by D.M. Knipe and P.M. Howley (4th edn). Pp 2575-2628. Philadelphia: Lippincott Williams & Williams.
2. Cohen, J.I. (2000) "Epstein-Barr virus infection", New England Journal of Medicine, 343(7), 481-492.
3. Thorley-Lawson, D.A. and Gross, A. (2004) "Persistence of the Epstein-Barr virus and the origins of associated lymphomas", New England Journal of Medicine, 350(31), 1328-1337.
4. Rickinson, A.B. and Moss, D.J. (1997) "Human cytotoxic T lymphocyte responses to Epstein-Barr virus infection", Annual Review of Immunology, 15, 405-431.
5. Munz, C., Bickham, K.L., Subklewe, M., Tsang, M.L., Chahroudi, A., Kurilla, M.G., et al. (2000) "Human CD4(+) T lymphocytes consistently respond to the latent Epstein-Barr virus nuclear antigen EBNA1", Journal of Experimental Medicine, 191(10), 1649-1660.
6. Callan, M.F., Tan, L., Annels, N., Ogg, G.S., Wilson, J.D., O'Callaghan, C.A., et al. (1998) "Direct visualization of antigen-specific CD8+ T cells during the primary immune response to Epstein-Barr virus In vivo", Journal of Experimental Medicine, 187(9), 1395-1402.
7. Hsu, J.L. and Glaser, S.L. (2000) "Epstein-barr virus-associated malignancies: epidemiologic patterns and etiologic implications", Critical Review in Oncology and Hematology, 34 1), 27-53.
8. Rooney, C.M., Smith, C.A., Ng, C.Y., Loftin, S.K., Sixbey, J.W., Gan, Y., et al. (1998) "Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients", Blood, 92(5), 1549-1555.
9. Gu, S.Y., Huang, T.M., Ruan, L., Miao, Y.H., Lu, H., Chu, C.M., et al. (1995) "First EBV vaccine trial in humans using recombinant vaccinia virus expressing the major membrane antigen", Developments in Biological Standardization, 84, 171-177.
10. Khanna, R., Moss, D.J. and Burrows, S.R. (1999) "Vaccine strategies against Epstein-Barr virus-associated diseases: lessons from studies on cytotoxic T-cell-mediated immune regulation", Immunological Reviews, 170, 49-64.
11. Sitki-Green, D., Covington, M. and Raab-Traub, N. (2003) "Compartmentalization and transmission of multiple epstein-barr virus strains in asymptomatic carriers", Journal of Virology, 77 3), 1840-1847.
12. Kuppers, R. (2003) "B cells under influence: transformation of B cells by Epstein-Barr virus", Nature Reviews in Immunology, 3(10), 801-812.
13. Cesarman, E., Chadburn, A., Liu, Y.F., Migliazza, A., Dalla-Favera, R. and Knowles, D.M. (1998) "BCL-6 gene mutations in posttransplantation lymphoproliferative disorders predict response to therapy and clinical outcome", Blood, 92(7), 2294-2302.
14. Sokal, E.M., Antunes, H., Beguin, C., Bodeus, M., Wallemacq, P., de Ville, d.G., et al. (1997) "Early signs and risk factors for the increased incidence of Epstein-Barr virus-related posttransplant lymphoproliferative diseases in pediatric liver transplant recipients treated with tacrolimus", Transplantation, 64(10), 1438-1442.
15. Ho, M., Jaffe, R., Miller, G., Breinig, M.K., Dummer, J.S., Makowka, L., et al. (1988) "The frequency of Epstein-Barr virus infection and associated lymphoproliferative syndrome after transplantation and its manifestations in children", Transplantation 45(4), 719-727.
16. Curtis, R.E., Travis, L.B., Rowlings, P.A., Socie, G., Kingma, D.W., Banks, P.M., et al. (1999) "Risk of lymphoproliferative disorders after bone marrow transplantation: a multi-institutional study", Blood, 94(7), 2208-2216.
17. Bhatia, S., Ramsay, N.K., Steinbuch, M., Dusenbery, K.E., Shapiro, R.S., Weisdorf, D.J., et al. (1996) "Malignant neoplasms following bone marrow transplantation", Blood, 87(9), 3633-3639.
18. Stevens, S.J., Verschuuren, E.A., Pronk, I., van Der, B.W., Harmsen, M.C., The, T.H., et al. (2001) "Frequent monitoring of Epstein-Barr virus DNA load in unfractionated whole blood is essential for early detection of posttransplant lymphoproliferative disease in high-risk patients", Blood, 97(5), 1165-1171.
19. Rooney, C.M., Loftin, S.K., Holladay, M.S., Brenner, M.K., Krance, R.A. and Heslop, H.E. (1995) "Early identification of Epstein-Barr virus-associated post-transplantation lymphoproliferative disease", British Journal of Haematology, 89(1), 98-103.
20. Wagner, H.J., Cheng, Y.C., Huls, M.H., Gee, A.P., Kuehnle, I., Krance, R.A., et al. (2004) "Prompt versus Pre-emptive Intervention For EBV- Lymphoproliferative Disease", Blood, 103 10), 3979-81.
21. Rose, C., Green, M., Webber, S., Ellis, D., Reyes, J. and Rowe, D. (2001) "Pediatric solid-organ transplant recipients carry chronic loads of epstein-barr virus exclusively in the immunoglobulin d-negative b-cell compartment", Journal of Clinical Microbiology, 39(4), 1407-1415.
22. Clave, E., Agbalika, F., Bajzik, V., de Latour, R.P., Trillard, M., Rabian, C., et al. (2004) "Epstein-Barr virus (EBV) reactivation in allogeneic stem-cell transplantation: relationship between viral load, EBV-specific T-cell reconstitution and rituximab therapy", Transplantation, 77(1), 76-84.
23. Meij, P., Van Esser, J.W., Niesters, H.G., van Baarle, D., Miedema, F., Blake, N., et al. (2003) "Impaired recovery of Epstein-Barr virus (EBV)-specific CD8+ T lymphocytes after partially T-depleted allogeneic stem cell transplantation may identify patients at very high risk for progressive EBV reactivation and lymphoproliferative disease", Blood, 101(11), 4290-4297.
24. Fischer, A., Blanche, S., Le Bidois, J., Bordigoni, P., Garnier, J.L., Niaudet, P., et al. (1991) "Anti-B-cell monoclonal antibodies in the treatment of severe B-cell lymphoproliferative syndrome following bone marrow and organ transplantation", New England Journal of Medicine, 324(21), 1451-1456.
25. Faye, A., Quartier, P., Reguerre, Y., Lutz, P., Carret, A.S., Dehee, A., et al. (2001) "Chimaeric anti-CD20 monoclonal antibody (rituximab) in post-transplant B-lymphoproliferative disorder following stem cell transplantation in children", British Journal of Haematology, 115(1), 112-118.
26. Straathof, K.C., Savoldo, B., Heslop, H.E. and Rooney, C.M. (2002) "Immunotherapy for post-transplant lymphoproliferative disease", British Journal of Haematology, 118(3), 728-740.
27. Heslop, H.E., Brenner, M.K. and Rooney, C.M. (1994) "Donor T cells to treat EBV-associated lymphoma", New England Journal of Medicine, 331(10), 679-680.
28. Lucas, K.G., Burton, R.L., Zimmerman, S.E., Wang, J., Cornetta, K.G., Robertson, K.A., et al. (1998) " Semiquantitative Epstein-Barr virus (EBV) polymerase chain reaction for the determination of patients at risk for EBV-induced lymphoproliferative disease after stem cell transplantation", Blood, 91(10), 3654-3661.
29. O'Reilly, R.J., Small, T.N., Papadopoulos, E., Lucas, K., Lacerda, J. and Koulova, L. (1997) "Biology and adoptive cell therapy of Epstein-Barr virus-associated lymphoproliferative disorders in recipients of marrow allografts", Immunological Reviews, 157, 195-216.
30. Papadopoulos, E.B., Ladanyi, M., Emanuel, D., MacKinnon, S., Boulad, F., Carabasi, M.H., et al. (1994) "Infusions of donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation", New England Journal of Medicine, 330(17), 1185-1191.
31. Gross, T.G., Steinbuch, M., DeFor, T., Shapiro, R.S., McGlave, P., Ramsay, N.K., et al. (1999) "B cell lymphoproliferative disorders following hematopoietic stem cell transplantation: risk factors, treatment and outcome", Bone Marrow Transplantation, 23(3), 251-258.
32. Nagafuji, K., Eto, T., Hayashi, S., Oshima, K., Maeda, Y., Gondo, H., Inamura, T. and Niho, Y. (1998) "Donor lymphocyte transfusion for the treatment of Epstein-Barr virus-associated lymphoproliferative disorder of the brain", Bone Marrow Transplantation, 21(11), 1155-1158.
33. Porter, D.L., Orloff, G.J. and Antin, J.H. (1994) "Donor mononuclear cell infusions as therapy for B-cell lymphoproliferative disorder following allogeneic bone marrow transplant", Transplantation Science, 4(1), 12-14.
34. Bonini, C., Ferrari, G., Verzeletti, S., Servida, P., Zappone, E., Ruggieri, L., et al. (1997) "HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia", Science, 276(5319), 1719-1724.
35. Tiberghien, P., Ferrand, C., Lioure, B., Milpied, N., Angonin, R., Deconinck, E., et al. (2001) "Administration of herpes simplex-thymidine kinase-expressing donor T cells with a T-cell-depleted allogeneic marrow graft", Blood, 97(1 , 63-72.
36. Straathof, K.C., Spencer, D.M., Sutton, R.E. and Rooney, C.M. (2003) "Suicide genes as safety switches in T lymphocytes", Cytotherapy, 5(3), 227-230.
37. Heslop, H.E., Ng, C.Y., Li, C., Smith, C.A., Loftin, S.K., Krance, R.A., et al. (1996) "Long-term restoration of immunity against Epstein-Barr virus infection by adoptive transfer of gene-modified virus-specific T lymphocytes", Nature Medicine, 2 5), 551-555.
38. Gottschalk, S., Ng, C.Y., Perez, M., Smith, C.A., Sample, C., Brenner, M.K., et al. (2001) "An Epstein-Barr virus deletion mutant associated with fatal lymphoproliferative disease unresponsive to therapy with virus-specific CTLs", Blood, 97(4), 835-843.
39. Gustafsson, A., Levitsky, V., Zou, J.Z., Frisan, T., Dalianis, T., Ljungman, P., et al. (2000) "Epstein-Barr virus (EBV) load in bone marrow transplant recipients at risk to develop post-transplant lymphoproliferative disease: prophylactic infusion of EBV-specific cytotoxic T cells", Blood, 95(3), 807-814.
40. Comoli, P., Labirio, M., Basso, S., Baldanti, F., Grossi, P., Furione, M., et al. (2002) "Infusion of autologous Epstein-Barr virus (EBV)-specific cytotoxic T cells for prevention of EBV-related lymphoproliferative disorder in solid organ transplant recipients with evidence of active virus replication", Blood, 99(7), 2592-2598.
41. Haque, T., Amlot, P.L., Helling, N., Thomas, J.A., Sweny, P., Rolles, K., et al. (1998) "Reconstitution of EBV-specific T cell immunity in solid organ transplant recipients", Journal of Immunology 160(12), 6204-6209.
42. Savoldo, B., Huls, M.H., Lopez, T., Caldwell, Y., Finegold, M., Goss, J., et al. (2002) "Specific cytotoxic T lymphocytes (CTL) Infusions as early intervention for liver transplant recipients with lymphoproliferative disease", Blood, 100(11), 363a.
43. Sherritt, M.A., Bharadwaj, M., Burrows, J.M., Morrison, L.E., Elliott, S.L., Davis, J.E., et al. (2003) "Reconstitution of the latent T-lymphocyte response to Epstein-Barr virus is coincident with long-term recovery from posttransplant lymphoma after adoptive immunotherapy", Transplantation, 75(9), 1556-1560.
44. Khanna, R., Bell, S., Sherritt, M., Galbraith, A., Burrows, S.R., Rafter, L., et al. (1999) "Activation and adoptive transfer of Epstein-Barr virus-specific cytotoxic T cells in solid organ transplant patients with posttransplant lymphoproliferative disease" , Proceedings of the National Academy of Sciences USA, 96(18), 10391-10396.
45. Metes, D., Storkus, W., Zeevi, A., Patterson, K., Logar, A., Rowe, D., et al. (2000) "Ex vivo generation of effective Epstein-Barr virus (EBV)-specific CD8+ cytotoxic T lymphocytes from the peripheral blood of immunocompetent Epstein Barr virus-seronegative individuals", Transplantation, 70(10), 1507-1515.
46. Savoldo, B., Cubbage, M.L., Durett, A.G., Goss, J., Huls, M.H., Liu, Z., et al. (2002) "Generation of EBV-specific CD4+ cytotoxic T cells from virus naive individuals", Journal of Immunology, 168(2), 909-918.
47. Haque, T., Wilkie, G.M., Taylor, C., Amlot, P.L., Murad, P, Iley, A., et al. (2002) "Treatment of Epstein-Barr-virus-positive post-transplantation lymphoproliferative disease with partly HLA-matched allogeneic cytotoxic T cells", Lancet, 360(9331), 436-442.
48. Sun, Q., Burton, R., Reddy, V. and Lucas, K.G. (2002) "Safety of allogeneic Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes for patients with refractory EBV-related lymphoma", British Journal of Haematology, 118(3), 799-808.
49. Nalesnik, M.A., Rao, A.S., Furukawa, H., Pham, S., Zeevi, A., Fung, J.J., et al. (1997) "Autologous lymphokine-activated killer cell therapy of Epstein-Barr virus-positive and -negative lymphoproliferative disorders arising in organ transplant recipients", Transplantation, 63(9), 1200-1205.
50. Herbst, H., Dallenback, F., Hummel, M., Niedobitek, G., Pileri, S., Nuller-Lantzsch, N. and Stein, H. (1991) "Epstein-Barr virus latent membrane protein expression in Hodgkin and Reed-Sternberg cells", Proceedings of the National Academy of Sciences USA, 88, 4766-4770.
51. Roskrow, M.A., Suzuki, N., Gan, Y.-J., Sixbey, J.W., Ng, C.Y.C., Kimbrough, S., et al. (1998) "EBV-specific cytotoxic T lymphocytes for the treatment of patients with EBV positive relapsed Hodgkin's disease", Blood, 91, 2925-2934.
52. Gottschalk, S., Heslop, H.E. and Rooney, C.M. (2002) "Treatment of Epstein-Barr virus-associated malignancies with specific T cells", Advances in Cancer Research, 84, 175-201.
53. Bollard, C.M., Straathof, K., Huls, M.H., Lacuesta, K., Gresik, M., Carrum, G., et al. (2003) "Cytotoxic T lymphocyte therapy for EBV positive Hodgkin's disease", Blood, 102(11), 901a.
54. Lucas, K.G., Salzman, D., Garcia, A. and Sun, Q. (2004) "Adoptive immunotherapy with allogeneic Epstein-Barr virus (EBV)-specific cytotoxic T-lymphocytes for recurrent, EBV-positive Hodgkin disease", Cancer, 100(9), 1892-1901.
55. Gahn, B., Siller-Lopez, F., Pirooz, A.D., Yvon, E., Gottschalk, S., Longnecker, R., et al. (2001) "Adenoviral gene transfer into dendritic cells efficiently amplifies the immune response to LMP2A antigen: a potential treatment strategy for Epstein-Barr virus-positive Hodgkin's lymphoma", International Journal of Cancer 93(5), 706-713.
56. Ranieri, E., Herr, W., Gambotto, A., Olson, W., Rowe, D., Robbins, P.D., et al. (1999) "Dendritic cells transduced with an adenovirus vector encoding Epstein-Barr virus latent membrane protein 2B: a new modality for vaccination", Journal of Virology, 73 12), 10416-10425.
57. Su, Z., Peluso, M.V., Raffegerst, S.H., Schendel, D.J. and Roskrow, M.A. (2001) "The generation of LMP2a-specific cytotoxic T lymphocytes for the treatment of patients with Epstein-Barr virus-positive Hodgkin disease", European Journal of Immunology, 31(3), 947-958.
58. Gottschalk, S., Edwards, O.L., Sili, U., Huls, M.H., Goltsova, T., Davis, A.R., et al. (2003) "Generating CTLs against the subdominant Epstein-Barr virus LMP1 antigen for the adoptive immunotherapy of EBV-associated malignancies", Blood, 101 5), 1905-1912.
59. Duraiswamy, J., Sherritt, M., Thomson, S., Tellam, J., Cooper, L., Connolly, G., et al. (2003) "Therapeutic LMP1 polyepitope vaccine for EBV-associated Hodgkin disease and nasopharyngeal carcinoma", Blood, 101(8), 3150-3156.
60. Duraiswamy, J., Bharadwaj, M., Tellam, J., Connolly, G., Cooper, L., Moss, D., et al. (2004) "Induction of therapeutic T-cell responses to subdominant tumor-associated viral oncogene after immunization with replication-incompetent polyepitope adenovirus vaccine", Cancer Research, 64(4), 1483-1489.
61. Bollard, C.M., Straathof, K., Huls, M.H., Leen, A., Lacuesta, K., Davis, A., et al. (2004) "The generation and characterization of LMP2-specific CTLs for use as adoptive transfer from patients with relapsed EBV-positive Hodgkin disease", Journal of Immunotherapy, 27(4), 317-327.
62. Bollard, C.M., Rossig, C., Calonge, M.J., Huls, M.H., Wagner, H.J., Massague, J., et al. (2002) "Adapting a transforming growth factor beta-related tumor protection strategy to enhance antitumor immunity", Blood, 99(9), 3179-3187.
63. Wagner, H.J., Bollard, C.M., Vigouroux, S., Huls, M.H., Anderson, R., Prentice, H.G., et al. (2004) "A strategy for treatment of Epstein-Barr virus-positive Hodgkin's disease by targeting interleukin 12 to the tumor environment using tumor antigen-specific T cells", Cancer Gene Therapy, 11(2), 81-91.
64. Raab-Traub, N. (2002) "Epstein-Barr virus in the pathogenesis of NPC", Seminars in Cancer Biology, 12(6), 431-441.
65. Lin, C.L., Lo, W.F., Lee, T.H., Ren, Y., Hwang, S.L., Cheng, Y.F., et al. (2002) "Immunization with Epstein-Barr Virus (EBV) peptide-pulsed dendritic cells induces functional CD8+ T-cell immunity and may lead to tumor regression in patients with EBV-positive nasopharyngeal carcinoma", Cancer Research, 62(23), 6952-6958.
66. Taylor, G.S., Haigh, T.A., Gudgeon, N.H., Phelps, R.J., Lee, S.P., Steven, N.M. and Rickinson, A.B. (2004) "Dual stimulation of Epstein-Barr Virus (EBV)-specific CD4+- and CD8+-T-cell responses by a chimeric antigen construct: potential therapeutic vaccine for EBV-positive nasopharyngeal carcinoma", Journal of Virology, 78 2), 768-778.
67. Comoli, P., De Palma, R., Siena, S., Nocera, A., Basso, S., Del Galdo, F., et al. (2004) "Adoptive transfer of allogeneic Epstein-Barr virus (EBV)-specific cytotoxic T cells with in vitro antitumor activity boosts LMP2-specific immune response in a patient with EBV-related nasopharyngeal carcinoma", Annals in Oncology, 15 1), 113-117.
68. Hecht, J.L. and Aster, J.C. (2000) "Molecular biology of Burkitt's lymphoma", Journal of Clinical Oncology, 18(21), 3707-3721.
69. Lee, S.P., Brooks, J.M., Al Jarrah, H., Thomas, W.A., Haigh, T.A., Taylor, G.S., et al. (2004) "CD8 T cell recognition of endogenously expressed epstein-barr virus nuclear antigen 1", Journal of Experimental Medicine, 199(10), 1409-1420.
70. Voo, K.S., Fu, T., Wang, H.Y., Tellam, J., Heslop, H.E., Brenner, M.K., et al. (2004) "Evidence for the Presentation of Major Histocompatibility Complex Class I-restricted Epstein-Barr Virus Nuclear Antigen 1 Peptides to CD8+ T Lymphocytes", Journal of Experimental Medicine, 199(4), 459-470.
71. Levitskaya, J., Coram, M., Levitsky, V., Imreh, S., Steigerwald-Mullen, P.M., Klein, G., et al. (1995) " Inhibition of antigen processing by the internal repeat region of the Epstein-Barr virus nuclear antigen-1", Nature, 375(6533), 685-688.
72. Yin, Y., Manoury, B. and Fahraeus, R. (2003) "Self-inhibition of synthesis and antigen presentation by Epstein-Barr virus-encoded EBNA1", Science 301(5638), 1371-1374.
73. Leen, A., Meij, P., Redchenko, I., Middeldorp, J., Bloemena, E., Rickinson, A. and Blake, N. (2001) "Differential immunogenicity of Epstein-Barr virus latent-cycle proteins for human CD4(+) T-helper 1 responses", Journal of Virology, 75(18), 8649-8659.
74. Paludan, C., Bickham, K., Nikiforow, S., Tsang, M.L., Goodman, K., Hanekom, W.A., et al. (2002) "Epstein-Barr nuclear antigen 1-specific CD4(+) Th1 cells kill Burkitt's lymphoma cells", Journal of Immunology, 169(3), 1593-1603.
75. Munz, C. (2004) "Epstein-barr virus nuclear antigen 1: from immunologically invisible to a promising T cell target", Journal of Experimental Medicine, 199(10), 1301-1304.
76. Orentas, R.J., Roskopf, S.J., Nolan, G.P. and Nishimura, M.I. (2001) "Retroviral transduction of a T cell receptor specific for an Epstein-Barr virus-encoded peptide", Clinical Immunology, 98 2), 220-228.
77. Tao, Q. and Robertson, K.D. (2003) "Stealth technology: how Epstein-Barr virus utilizes DNA methylation to cloak itself from immune detection", Clinical Immunology, 109(1), 53-63.
78. Israel, B.F. and Kenney, S.C. (2003) "Virally targeted therapies for EBV-associated malignancies", Oncogene, 22 33), 5122-5130.
79. Feng, W.H., Israel, B., Raab-Traub, N., Busson, P. and Kenney, S.C. (2002) "Chemotherapy induces lytic EBV replication and confers ganciclovir susceptibility to EBV-positive epithelia cell tumors", Cancer Research, 62(6), 1920-1926.
80. Sangiolo, D., Nash, R.A., Jensen, M.C., Lesnikova, M. Bukovsky, A., Nikitine, A. and Georges, G.E. (2003) "Sequential lentiviral transduction conferring simulataneous sensitivity to ganciclovir (GCV) and resistance to mycophenolate (MMF)", Blood, 102(11), 993a.
81. Dudley, M.E., Wunderlich, J.R., Robbins, P.F., Yang, J.C., Hwu, P., Schwartzentruber, D.J., et al. (2002) "Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes", Science, 298(5594), 850-854.
82. Emanuel, D.J., Lucas, K.G., Mallory, G.B., Edwards-Brown, M.K., Pollok, K.E., Conrad, P.D., et al. (1997) "Treatment of posttransplant lymphoproliferative disease in the central nervous system of a lung trasnplant recipient using allogeneic leucocytes", Transplantation, 63(11), 1691-1694.
83. Chua, D., Huang, J., Zheng, B., Lau, S.Y., Luk, W., Kwong, D.L., et al. (2001) "Adoptive transfer of autologous Epstein-Barr virus-specific cytotoxic T cells for nasopharyngeal carcinoma", International Journal of Cancer, 94(1), 73-80.
84. Straathof, K., Bollard, C.M., Popat, U.R., Huls, M.H., Zhang, L., Morriss, M.C., et al. (2003) "Cytotoxic T lymphocytes for Epstein Barr virus-positive nasopharyngeal carcinoma", Blood, 102(11), 125a.